ArticleJournal of anesthesia and translational medicine2026
CD36 is associated with myocardial ischemia-reperfusion-induced renal injury in diabetic rats, accompanied by alterations in the PI3K/Akt/eNOS pathway.
Article in Journal of anesthesia and translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: CD36, a lipid transporter, is markedly upregulated in the diabetic kidney. However, whether CD36 contributes to renal injury following myocardial ischemia-reperfusion (I/R) in diabetes remains unknown. This study aimed to identify the role of CD36 in myocardial I/R-induced renal injury in diabetic rats and to investigate the mechanisms involved. Methods: Type 1 diabetic rats received intravenous SSO, a CD36 inhibitor, and were then subjected to myocardial ischemia-reperfusion (I/R) with ischemic postconditioning. Cardiac and renal function, tissue injury markers, and oxidative stress were assessed using commercial assay kits. Protein expression was analyzed by Western blotting. Results: After myocardial I/R, oxidative stress increased and renal function deteriorated. CD36 and the PI3K/Akt/eNOS pathway were upregulated in the kidney, potentially reflecting a compensatory protective response. SSO, a CD36 inhibitor, reduced myocardial injury, lowered renal CD36 and p-Akt/p-eNOS expression, and attenuated renal injury, indicating that its renoprotective effect was largely secondary to cardioprotection. In contrast, ischemic postconditioning conferred little protection in diabetic rats. Conclusions: These findings indicate that CD36 is upregulated in the kidney after myocardial I/R in diabetic rats, accompanied by alterations in the PI3K/Akt/eNOS pathway as a compensatory response. CD36 inhibition by SSO reduced myocardial injury and, in turn, attenuated renal injury, suggesting that CD36 is associated with myocardial I/R-induced renal injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.